It was doing poorly with the warning of rare liver problems and now with this other warning it's hard to say how much more weakness you'll see there.

196

This is most concerning as it's the third late-stage failure they've had in the past year.

196

It is still too early to know if (Merck) will be able to win cases on a consistent basis.

168

If you've misjudged what's happened in '05, how can you give guidance for '06 and '07 with any confidence.

153

If you had a generic Lipitor, it would be harder for Vytorin to compete. When you have a generic out there, you start worrying about therapeutic substitution.

141

If you've misjudged what's happened in 2005, how can you give guidance for 2006 and 2007?

123

We're not expecting any revenue impact in the third quarter or the fourth quarter.

121

Therapeutic substitution - substituting one product for another in the same class - just hasn't happened yet.

103

It certainly looks like Clark is willing to make tough decisions. I think eliminating 11 percent of the company is a big, major step for them. It will be really hard to maintain the corporate culture with so many positions being eliminated.

103